https://doi.org/10.55788/c3b499ac
Prof. Cesar Herrera (Montefiore-Einstein Center for Heart and Vascular Care, NY, USA) presented the new 2-year analysis from the Global Heart Attack Treatment Initiative (GHATI), which compared deidentified patient information from 2019 to 2021 [1]. At 2 years, GHATI had tracked treatment metrics from >4,000 patients with ST-elevation myocardial infarction (STEMI) from 39 medical centres in 18 countries in low-middle income countries on 5 continents.
The results showed significant improvements in the clinical combined endpoints of shock on arrival, arrest before/after intervention, the incidence of ejection fraction <40%, and survival rates at discharge since the start of the programme. High rates of reperfusion therapy (95%) were observed, and the study reported good adherence to guideline-directed medical therapy (92%). Prof. Herrera also remarked that the time was <90 minutes from the point of first medical contact to percutaneous coronary intervention for at least 75% of patients who required that intervention, which was better than anticipated. The recommended goal of achieving reperfusion within 90 minutes for at least 90% of STEMI patients is still an opportunity for further improvement in the future.
“The great thing about registries is that once you tell people what you are measuring and why, just the fact that people are measuring and caring about those metrics can have a tremendous effect (on performance),” Dr Herrera said. “To see the continuing improvements over time is pretty amazing.”
- Herrera CJ, et al. Improving STEMI Management Internationally: Two-year Report Of 4,015 Patients Enrolled In The American College Of Cardiology - Global Heart Attack Treatment Initiative (GHATI). Abstract 410–08, ACC 2022, 2–4 April, Washington DC, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Sodium thiosulfate ineffective at cardiac protection Next Article
No FLAVOUR difference between FFR and IVUS for PCI guidance »
« Sodium thiosulfate ineffective at cardiac protection Next Article
No FLAVOUR difference between FFR and IVUS for PCI guidance »
Table of Contents: ACC 2022
Featured articles
Alirocumab significantly reduces high-risk coronary plaques
Highlighted Original Research
POISE-3: Tranexamic acid for non-cardiac surgery
Treating chronic mild hypertension during pregnancy leads to better outcomes
New VOYAGER PAD data: Should patients with both PAD and CKD get rivaroxaban?
Alirocumab significantly reduces high-risk coronary plaques
Aggressive warming during non-cardiac surgery does not improve outcomes
Heart Failure and Cardiomyopathy
DIAMOND trial: Patiromer lowers risk of severe hyperkalaemia
Replacing septal reduction therapy with mavacamten for HCM
Omecamtiv mecarbil does not impact exercise capacity of patients with HFrEF
Symptomatic obstructive hypertrophic cardiomyopathy: long-term mavacamten control
Interventional and Structural Cardiology
COMPLETE revascularisation improves angina-related QoL
Plot twist for negative FAME 3 results: early QoL benefits of PCI
1-year CLASP TR results support tricuspid regurgitation repair
Head-to-head: post-TAVR edoxaban not better than DAPT
Chocolate Touch vs Lutonix catheters
No FLAVOUR difference between FFR and IVUS for PCI guidance
Myocardial Infarction
Low-resource countries benefit from global STEMI initiative
Sodium thiosulfate ineffective at cardiac protection
ICM-guided management did not improve MACE after MI
Prevention
PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation
RCT-IVVE trial: Do HF patients benefit from annual flu shots?
TRANSLATE-TIMI 70: Primary endpoint met but safety concerns for vupanorsen
Lipoprotein(a) slashed by 98% in APOLLO trial
Dietary intervention from your supermarket
Related Articles
June 15, 2022
ICM-guided management did not improve MACE after MI
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com